Receive exclusive offers by SMS. Our AI assistant answers your texts.Opt in

← Back to Blog
Nov 6, 2026 ET

What Are Research Peptides? Definition, Label and FDA Status

What Are Research Peptides? Definition, Label and FDA Status
The following blog post is for entertainment and informational purposes only. It is not intended to provide medical advice or diagnosis. Please consult your doctor before making any health-related decisions.

Research peptides are short chains of amino acids sold online under a "for research use only" label, a statement that they are not intended for human use. As of November 2026, products sold this way are not FDA-approved drugs. They are not manufactured or tested to pharmaceutical standards, and their purity, dose accuracy, sterility, and composition can differ from what the label claims. This complete guide to research peptides explains what the label means, what research has studied, each molecule's regulatory status and the risks of research-use-only products.

Valhalla Vitality does not sell research-use-only products. Discussion of a substance in this article does not mean it is available through Valhalla Vitality.

What does "research use only" mean?

"For research use only" (RUO) is a labeling statement that a product is not intended for human use, not an FDA approval or a safety classification. The label does not mean what many buyers assume.

In August 2026, FDA's Center for Drug Evaluation and Research sent warning letters to multiple online peptide sellers whose products carried "research use only" and "not for human consumption" labeling. FDA concluded that evidence from those sellers' websites established the products were intended as drugs for human use, making them unapproved new drugs under section 505(a) of the FD&C Act, and that introducing them into interstate commerce violates sections 301(d) and 505(a).

What does the label actually verify? Very little. It does not verify that the contents match what is printed, and it is not evidence of pharmaceutical manufacturing standards, sterility testing, or FDA review. In one August 2026 warning letter, FDA noted that a seller marketed bacteriostatic water alongside a "peptide guide" and "peptide calculator," which together "provide the means to prepare an injectable drug for human administration," indicating the products were intended for human use regardless of the label.

Across its 2023-2026 warning letters, FDA has found that a "research use only" label does not prevent a product from being an unapproved drug when evidence, such as the seller's website, shows it is intended for human use. A March 2026 warning letter cited website statements as evidence of intended use "as defined in 21 CFR 201.128," even though the products were labeled "Research Use Only." A December 2024 warning letter reached the same conclusion for peptide products labeled "intended as a research chemical only." For how the two labels compare, see research peptides vs research chemicals.

What research has studied

Peptides have been the subject of laboratory and clinical research across several biological areas. This section covers what types of studies exist, who was studied, and what limitations those studies carry; it is not a list of uses for products sold as research peptides. It does not imply that these findings establish safety or effectiveness for human use of research-labeled products.

Peptides as a broad class of molecules have been studied in the following contexts; these studies did not test products sold online as research peptides:

  • Antimicrobial activity: certain peptide classes have been examined in research on bacterial pathogens, including strains associated with oral infections.
  • Metabolic signaling: peptide hormone analogues have been studied in glucose metabolism; FDA-approved prescription medicines containing semaglutide or tirzepatide exist for specific conditions.
  • Cardiovascular function: cardiac natriuretic peptides have been studied as biomarkers and in contexts related to heart failure.

Preclinical research and its limits

For some peptides sold with a research-use-only label, the studies FDA has reviewed are limited to cell and animal models. For MOTS-c, FDA's July 2026 briefing found that the nonclinical pharmacology studies it reviewed were limited to in-vitro and rodent models, and FDA identified no clinical studies or human exposure data. Results from rodent and cell-line models do not establish safety or effectiveness in humans and may not generalize across species or routes of administration.

A 2023 review in the European Journal of Pharmaceutical Sciences described ongoing challenges in developing peptide drugs, including oral bioavailability. That context matters when evaluating claims associated with any research-labeled product.

Human data: what exists and what is missing

Human data is limited for many peptides sold with a research-use-only label. For BPC-157 and TB-500, FDA's July 2026 briefing documents found human safety information insufficient or absent.

For BPC-157, FDA's July 2026 Pharmacy Compounding Advisory Committee briefing stated that no approved product containing BPC-157 exists in any country. FDA said clinical safety information is insufficient to characterize BPC-157's safety profile, and the only human studies it identified were short-term and did not use the routes proposed for compounding. For TB-500, FDA's 2026 briefing stated it has not identified any clinical studies or human exposure data via any route of administration.

The distance between animal-model findings and verified human safety data is not a minor qualification. Neither BPC-157 nor TB-500 is a component of an FDA-approved drug.

Regulatory status as of November 2026

Products sold as research peptides are not approved by the FDA for human use. Regulatory status differs by molecule, and this section states each molecule's standing using only verified official sources. Generalizing across molecules is inaccurate: some share a name with an FDA-approved prescription drug; others are not FDA-approved drugs.

Molecules with FDA-approved prescription counterparts

For semaglutide, tirzepatide, tesamorelin, bremelanotide, somatropin, hCG, oxytocin, and teduglutide, an FDA-approved prescription medicine exists for specific medical conditions. Each requires a licensed provider's evaluation and is dispensed by a licensed pharmacy.

Products sold as research peptides containing those same molecules are not those approved drugs. The molecule name on a vial does not transfer the regulatory status of the approved version. FDA has warned companies selling semaglutide and tirzepatide under "for research purposes" labels, finding those products were sold for human use and were unapproved new drugs. Our overview of GLP-1 research peptides covers those findings in more detail.

Sermorelin's prescription product was previously FDA-approved for treating growth hormone deficiency in children. The manufacturer discontinued it, and FDA withdrew approval effective June 18, 2009. Research-labeled sermorelin products are not approved by the FDA for human use.

Molecules with no approved human use

None of the following molecules is FDA-approved as of November 2026:

  • BPC-157: No approved product exists in any country, per FDA's July 2026 briefing. FDA has stated that compounded BPC-157 may pose a risk for immunogenicity for certain routes of administration and that it lacks sufficient information to know whether the drug would cause harm in humans. It is one of six peptides covered by the October 30, 2026 HHS interim compounding policy described below, which is not FDA approval.
  • TB-500: Not a component of any FDA-approved drug. FDA found no clinical studies or human exposure data for any route of administration. It is also one of the six peptides in that HHS interim policy, which is not FDA approval.
  • Ipamorelin: Not FDA-approved. FDA placed ipamorelin acetate in Category 2 under its 503B interim policy on September 29, 2023, citing potential immunogenicity risk and a published study identifying serious adverse events, including death, when given intravenously.
  • CJC-1295: Not FDA-approved. FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes that available clinical data are limited.
  • GHRP-2 and GHRP-6: Not FDA-approved. GHRP-6, and GHRP-2 for certain routes of administration, were placed in Category 2 for outsourcing-facility (503B) compounding on September 29, 2023, with FDA citing a possible immunogenicity risk for both.
  • AOD-9604: Not FDA-approved. FDA says compounded AOD-9604 may pose a significant immunogenicity risk for certain routes of administration and has identified serious adverse events, though causality is not clear.
  • Retatrutide: Investigational; not FDA-approved for any use. As of November 2026, ClinicalTrials.gov lists 14 Phase 3 studies of retatrutide, and no approval is in effect. The HHS interim compounding policy does not apply to retatrutide. Its status is covered in more detail in our retatrutide research peptide article.

BPC-157, TB-500 and the October 2026 HHS compounding policy

On October 30, 2026, HHS published in the Federal Register an interim enforcement-discretion policy for 503A compounding using six peptide bulk drug substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Under it, HHS does not intend to take enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding with these substances, but only when all of the policy's conditions are met.

Those conditions include identity limits and certain dosage forms or routes listed in the policy, FDA-registered sources with a certificate of analysis, a single active ingredient, adverse-event reporting, required labeling, a patient-specific prescription and all other FD&C Act requirements.

The policy is not FDA approval, not a finding of safety or effectiveness, not broad authorization or legalization, and not a listing on the 503A bulks list. It is interim: it applies only until a final rule addresses whether each peptide is included on the 503A bulks list, and HHS says it may revisit the policy if a safety signal or product quality issue arises. HHS also states that compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.

HHS states that the policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients. It does not make research-use-only products acceptable for human use, and FDA's warning-letter findings about research-labeled products still stand.

BPC-157 and TB-500 were previously in Category 2 of FDA's list of bulk drug substances that may present significant safety risks, and FDA's page now lists them under "nominated but withdrawn" after their nominators withdrew the nominations. FDA's July 2026 briefing documents proposed that neither be included on the 503A bulks list. The policy does not apply to any other peptide discussed in this article, including retatrutide, ipamorelin, CJC-1295, GHRP-2, GHRP-6 and AOD-9604. HHS states that compounded drugs may pose risks to patients. Availability of any compounded therapy depends on the specific product, formulation, current regulatory requirements, pharmacy eligibility and provider evaluation.

Risks of research-use-only products

Research-labeled peptides are not manufactured or tested to pharmaceutical standards. FDA warning letters and consumer guidance describe the specific quality and safety risks that may follow from this gap.

  • Purity is unknown: a label claiming a specific purity percentage is not independent regulatory verification, and the contents may differ from what is printed.
  • Dose accuracy cannot be assumed: products that have circumvented regulatory safeguards may contain varying amounts of active ingredients.
  • Sterility is not verified: unapproved products do not undergo FDA's review for safety, effectiveness, and quality before they are marketed.
  • Composition may differ entirely: FDA has warned that products circumventing regulatory safeguards may contain different ingredients altogether.
  • No pre-use medical screening: self-use means no assessment of health history, no contraindication check, and no baseline review before starting.
  • No clinical supervision: there is no licensed provider monitoring outcomes once use begins.

FDA states that injectable drug products can pose risks of serious harm because they are delivered directly into the body, sometimes directly into the bloodstream, and bypass some of the body's key defenses against toxins and microorganisms, which can lead to serious and life-threatening conditions.

What a label cannot tell you

A vial label showing a weight, concentration, or country-of-origin claim tells you nothing about what is actually inside. Labels like "10mg vial" or claims about domestic sourcing are not independent regulatory verification. They do not substitute for pharmaceutical testing.

A seller's certificate of analysis is not a government inspection. FDA has warned that products that have circumvented regulatory safeguards may be contaminated, may contain varying amounts of active ingredients, or may contain different ingredients altogether. The phrase "made in USA" on a research peptide vial is a seller's claim, not a compliance certificate.

Key points: research peptides as of November 2026

  • "For research use only" is a labeling statement that a product is not intended for human use. It is not an FDA approval, and FDA's warning letters through August 2026 found research-labeled products to be unapproved new drugs when evidence showed they were intended for human use.
  • Products sold as research peptides are not FDA-approved drugs, even when the label names a molecule that an approved medicine contains. For some molecules, such as semaglutide and tirzepatide, an FDA-approved prescription medicine exists for specific conditions.
  • BPC-157, TB-500, ipamorelin, CJC-1295, GHRP-2, GHRP-6, AOD-9604 and retatrutide are not FDA-approved drugs, and their safety in humans has not been established.
  • The October 30, 2026 HHS interim policy covers 503A compounding with six peptides only when all of its conditions are met. It is not FDA approval and does not make research-use-only products acceptable for human use.

Questions about any medication or supplement are best discussed with a licensed healthcare professional.

FAQ

What are research peptides?

Research peptides are short chains of amino acids sold online with a "for research use only" label, a statement that they are not intended for human use. They are not approved by the FDA for human use and are not manufactured or tested to pharmaceutical standards. The label does not verify purity, potency, or sterility.

Are research peptides FDA approved?

No. As of November 2026, products sold as research peptides are not FDA-approved drugs, even when the label names a molecule found in an approved prescription medicine, such as semaglutide or tirzepatide. The molecule name on a vial does not transfer the approved version's regulatory status. The October 30, 2026 HHS interim compounding policy is not FDA approval.

Are research peptides legal to buy in the US?

The regulatory situation is complex and changes as FDA and HHS issue new guidance, policies and warning letters. The October 30, 2026 HHS interim compounding policy for six peptides is not FDA approval and does not make research-use-only products acceptable for human use. No legal conclusion about individual purchases can be provided here; for legal questions, consult an attorney or official FDA guidance, not a seller's website.

Can you use research peptides on yourself?

Products sold as research peptides are not intended for human use. Self-use means no medical screening for contraindications, no review of health history, and no clinical supervision. For research-labeled products, safety in humans has not been established, and for molecules such as BPC-157 and TB-500, FDA has cited insufficient or absent human safety data in its compounding safety assessments.

How are research peptides different from prescription medications?

Prescription medication is prescribed by a licensed provider after an evaluation and dispensed by a licensed pharmacy. Research-labeled peptides are sold without a provider's evaluation or any medical screening, and they are not FDA-approved drugs, regardless of what molecule name appears on the label.

Sources

Scientific literature:

  1. Ying X et al. (2023). Antimicrobial Peptides Targeting Streptococcus mutans: Current Research on Design, Screening and Efficacy. Current Microbiology. PubMed
  2. Shalmi TW et al. (2024). Cardiac natriuretic peptides. Advances in Clinical Chemistry. PubMed
  3. Luo X et al. (2023). Advancements, challenges and future perspectives on peptide-based drugs: Focus on antimicrobial peptides. European Journal of Pharmaceutical Sciences. PubMed

Regulatory sources:

  1. U.S. Food and Drug Administration. FDA warning letters database, letters to online peptide sellers (2023-2026). FDA.gov
  2. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 10/01/2026). FDA.gov
  3. U.S. Food and Drug Administration. Briefing document, BPC-157-related bulk drug substances, PCAC July 23-24, 2026. FDA.gov
  4. U.S. Food and Drug Administration. Briefing document, TB-500-related bulk drug substances, PCAC July 23-24, 2026. FDA.gov
  5. U.S. Food and Drug Administration. Briefing document, MOTS-c-related bulk drug substances, PCAC July 23-24, 2026. FDA.gov
  6. U.S. Food and Drug Administration. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026 (Introduction). FDA.gov
  7. Federal Register (U.S. Department of Health and Human Services). Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526, published October 30, 2026. FederalRegister.gov
  8. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendices A and B (interim policy, October 2026). HHS.gov
  9. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of 04/22/2026). FDA.gov
  10. DailyMed, U.S. National Library of Medicine. Semaglutide injection label, revised 5/2026. DailyMed
  11. DailyMed, U.S. National Library of Medicine. Tirzepatide injection label, revised 8/2026. DailyMed
  12. DailyMed, U.S. National Library of Medicine. Tesamorelin label, revised 3/2025. DailyMed
  13. DailyMed, U.S. National Library of Medicine. Bremelanotide injection label, revised 3/2024. DailyMed
  14. DailyMed, U.S. National Library of Medicine. Somatropin label, revised 7/2026. DailyMed
  15. DailyMed, U.S. National Library of Medicine. Oxytocin injection label, revised 8/2024. DailyMed
  16. DailyMed, U.S. National Library of Medicine. Chorionic gonadotropin label, revised 2/2025. DailyMed
  17. DailyMed, U.S. National Library of Medicine. Teduglutide label, revised 9/2025. DailyMed
  18. U.S. Government Publishing Office. Federal Register 78 FR 14095, Sermorelin acetate, March 4, 2013. GovInfo
  19. ClinicalTrials.gov, U.S. National Library of Medicine. Studies with intervention "retatrutide," queried 2026-11-06. ClinicalTrials.gov

This article is for educational purposes only and is not medical advice. Valhalla Vitality does not sell research-use-only products, and discussion of a substance in this article does not mean it is available through Valhalla Vitality. Availability of any compounded therapy depends on the specific product, formulation, current regulatory requirements, pharmacy eligibility and provider evaluation. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.

You May Also Like

What Are Research Peptides? Definition, Label and FDA Status | Valhalla Vitality